Skip to content Skip to footer
Subscribe Now

INSIGHTS+

PharmaShots' Key Highlights of Second Quarter 2022
PharmaShots’ Key Highlights of Second Quarter 2022
The second quarter of 2022 highlights major acquisitions in the pharma and biotech industry along with multiple approvals. Meanwhile, AstraZeneca’s Farxiga (dapagliflozin) meet its primary endpoints for heart failure with a preserved ejection fraction Starting with the latest acquisitions, Pfizer acquire Biohaven for ~$11.6B, GSK acquire Affinivax for ~$3.3B. The second quarter of the year…
June 30, 2022
Disease of the Month: Vitiligo Disease
Disease of the Month: Vitiligo Disease
25th June is celebrated as Vitiligo Awareness Day. Vitiligo is a long-term skin disorder in which skin loses its color and white patches develop on the skin. It can occur in any part of the body and the discolored area grows with time. If the affected white area is less than 5mm it is known as macules…
June 25, 2022
Top Performing Drug of 2021 - Revlimid (June Edition)
Top Performing Drug of 2021 – Revlimid (June Edition)
Active Ingredients: Lenalidomide Strength: 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg Dosage Form: Capsules Mechanism of Action: Angiogenic inhibitor First Approval: US (Dec 27, 2005), EU (14 Jun, 2007) Revenue Revlimid (lenalidomide) is one of the key products of Bristol-Myers Squibb (BMS) that represent a significant percentage of the company’s total revenue. Sales of…
June 23, 2022
Insights+ The US FDA New Drug Approvals in May 2022
Insights+: The US FDA New Drug Approvals in May 2022
The US FDA has approved 7 NDAs in May 2022, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 33 novel products in 2022 In May 2022, the major highlights drugs were Lilly's Mounjaro (tirzepatide) received the US FDA’s approval for the treatment of adults with Type 2…
June 16, 2022
Insights+ Key Biosimilars Events of May 2022
Insights+ Key Biosimilars Events of May 2022
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of May, JSR Life Sciences launches Similis Bio business…
June 2, 2022
Top Performing Drug of 2021 - Keytruda (May Edition)
Top Performing Drug of 2021 – Keytruda (May Edition)
Active Ingredients: Pembrolizumab Strength: 100 mg/4 mL (25 mg/mL) Dosage Form: Syringe, Vial Mechanism of Action: PD-1 ligands antagonists First Approval: US (Sep 4, 2014), EU (Jul 17, 2015) Revenue Keytruda (pembrolizumab) has been a key player in Merck & Co. immuno-oncology drugs for the past years – reaching nearly $17B in annual sales in 2021. Despite the dampening impact…
May 26, 2022
Insights+ The US FDA New Drug Approvals in April 2022
Insights+: The US FDA New Drug Approvals in April 2022
The US FDA has approved 6 NDAs in Apr 2022, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 26 novel products in 2022 In Apr 2022, the major highlights drugs were Vivjoa for Recurrent Vulvovaginal Candidiasis, Cuvrior for Stable Wilson’s Disease, Igalmi for Acute Treatment of Agitation…
May 19, 2022
Disease of the Month: Dengue Disease
Disease of the Month: Dengue Diseas
In India, 16 May is observed as National Dengue Day. Dengue is a mosquito-borne viral disease transmitted by female mosquitoes of the Aedes aegypti species infected by any of the four dengue virus serotypes (DENV-1, DENV-2, DENV-3, and DENV-4)2. These mosquitoes belong to the family Flaviviridae. They bite during the day. As per WHO reports,…
May 16, 2022
Insights+ Key Biosimilars Events of April 2022
Insights+ Key Biosimilars Events of April 2022
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of April, Alvotech resolved a European patent dispute with…
May 5, 2022
Top Performing Drug of 2021 - Humira (April Edition)
Top Performing Drug of 2021 – Humira (April Edition)
Active Ingredients: Adalimumab Strength: 40 mg/0.8 ml Dosage Form: Syringe, Vial Mechanism of Action: TNF-alpha inhibitors First Approval: US (Dec 31, 2002), EU (Aug 09, 2003) Revenue Humira (adalimumab) has been the top-selling biologic drug product for the last few years – reaching nearly $21B in annual sales in 2021. Humira is one of the main drivers of AbbVie’s immunology…
April 29, 2022
Load more